Pelthos Therapeutics Inc.
PTHS
$23.42
-$1.13-4.60%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 15.60M | 10.91M | 9.39M | 7.41M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.60M | 10.91M | 9.39M | 7.41M | -- |
| Cost of Revenue | 4.21M | 1.86M | 2.05M | 2.46M | 515.00K |
| Gross Profit | 11.39M | 9.05M | 7.34M | 4.95M | -515.00K |
| SG&A Expenses | 26.17M | 21.10M | 18.47M | 19.63M | 2.72M |
| Depreciation & Amortization | 1.04M | 1.03M | 877.00K | 679.00K | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.43M | 23.99M | 21.39M | 22.77M | 3.23M |
| Operating Income | -15.82M | -13.09M | -12.00M | -15.36M | -3.23M |
| Income Before Tax | -23.42M | -25.07M | -28.59M | -16.70M | -3.45M |
| Income Tax Expenses | -- | -- | -6.92M | -465.00K | -- |
| Earnings from Continuing Operations | -23.42M | -25.07M | -21.66M | -16.24M | -3.45M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.42M | -25.07M | -21.66M | -16.24M | -3.45M |
| EBIT | -15.82M | -13.09M | -12.00M | -15.36M | -3.23M |
| EBITDA | -14.50M | -11.59M | -10.79M | -15.01M | -- |
| EPS Basic | -6.62 | -7.57 | -6.87 | -5.30 | -5.29 |
| Normalized Basic EPS | -3.87 | -4.73 | -5.61 | -3.41 | -3.31 |
| EPS Diluted | -6.62 | -7.57 | -6.87 | -5.30 | -5.29 |
| Normalized Diluted EPS | -3.87 | -4.73 | -5.61 | -3.41 | -3.31 |
| Average Basic Shares Outstanding | 3.54M | 3.31M | 3.15M | 3.06M | 651.90K |
| Average Diluted Shares Outstanding | 3.54M | 3.31M | 3.15M | 3.06M | 651.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |